| Patient | Vincent van Gogh |
|---|---|
| Date of birth | 1990-03-30 |
| Identifiers | MRN HR-NI010-SYN; SSN (made up) 000-10-3198 |
| Document date | 2026-11-01 |
| Author | Elise Verhoeven, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care twelve days after discharge from a first psychiatric admission: provisional diagnosis, antipsychotic monitoring baseline, first-episode workup, alcohol, sleep, and safety planning. Concerns: He wants to understand what happened to him and to stop it happening again, and is frightened that it will; He wants to paint every day again and to be able to concentrate; He is worried about his drinking and his sleep. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aripiprazole 10 mg oral tablet, one tablet by mouth once daily (started in hospital) | One tablet by mouth once daily | Oral route | 2026-01-05 to 2026-02-02 | completed | S |
| Aripiprazole 15 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-02 to 2026-02-16 | completed | S |
| Naltrexone 50 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-02 | active | S |
| Thiamine 100 mg oral tablet, one tablet by mouth daily (started in hospital) | One tablet by mouth daily | Oral route | 2026-01-05 to 2026-07-20 | completed | S |
| Aripiprazole 10 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-16 | active | S |
| Propranolol 10 mg oral tablet, one tablet by mouth twice daily for akathisia | One tablet by mouth twice daily | Oral route | 2026-02-16 to 2026-03-02 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Brain MRI without contrast | 2026-02-02 to 2026-02-02 | completed | S |
| Sleep-deprived routine EEG | 2026-02-02 to 2026-02-02 | completed | S |
| Advance care planning conversation with a psychiatric advance directive, about 20 minutes | 2026-06-15 to 2026-06-15 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-06-15 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-06-15 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 2026-07-20 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1886 | Heavy drinking, probably both absinthe and wine, from his time in Paris | D (CLM-0009) |
| December 23, 1888 | First crisis, with confusion and an injury to his left ear; hospital care in Arles with several days in isolation; went home after about two weeks | D (CLM-0003, CLM-0004) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He wants to understand what happened to him and to stop it happening again, and is frightened that it will | active | S |
| He wants to paint every day again and to be able to concentrate | active | S |
| He is worried about his drinking and his sleep | active | S |
Most recent measures: Leukocytes [#/volume] in Blood by Automated count 6.4 on 2026-07-20; Hemoglobin [Mass/volume] in Blood 14.6 on 2026-07-20; MCV [Entitic mean volume] in Red Blood Cells by Automated count 95 on 2026-07-20; Platelets [#/volume] in Blood by Automated count 214 on 2026-07-20; Sodium [Moles/volume] in Serum or Plasma 137 on 2026-01-19; Potassium [Moles/volume] in Serum or Plasma 4.1 on 2026-01-19; Creatinine [Mass/volume] in Serum or Plasma 0.94 on 2026-01-19; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 108 on 2026-01-19; Fasting glucose [Mass/volume] in Serum or Plasma 94 on 2026-04-20; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-04-20; Cholesterol [Mass/volume] in Serum or Plasma 191 on 2026-04-20; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 112 on 2026-04-20; Cholesterol in HDL [Mass/volume] in Serum or Plasma 50 on 2026-04-20; Triglyceride [Mass/volume] in Serum or Plasma 142 on 2026-04-20; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 on 2026-07-20; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 on 2026-07-20; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 36 on 2026-07-20; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 2026-01-19; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 388 on 2026-01-19; Phosphatidylethanol [Mass/volume] in Blood 16 on 2026-07-20; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-06-15; Total score [AUDIT-C] 3 on 2026-06-15 [S]
Strengths and supports: Supports: a friend he paints with who lives nearby, and the coordinated specialty care team; his work is his strongest reason to get well. He decides who is told about his health [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First episode of psychosis with mood features: weeks of very little sleep, intense work and expansive plans, then acute confusion, hallucinations and suspiciousness with self-injury, and low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, brief psychotic or schizophreniform disorder, alcohol withdrawal delirium or alcohol-induced psychotic disorder, and psychosis related to focal epilepsy. Synthetic modern episode linked to his documented first crisis | active | provisional | F29 | S — Synthetic modern coding of the documented first crisis. Unspecified psychosis is coded because the cause is not yet established; the retrospective diagnoses stay in the claims. |
| Alcohol use disorder, moderate (heavy daily wine and anise spirits before the episode); synthetic modern episode linked to his documented heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding of the documented drinking and its retrospective interpretation. |
| Self-injury to the left ear during the acute confusional episode, without suicidal intent; wound healed after surgical care in hospital | active | confirmed | Z91.52 | S — Synthetic modern coding of the documented injury; no detail of the injury is recorded. |
| Akathisia from aripiprazole, two weeks after the dose was increased to 15 mg; treated by returning to 10 mg and short-term propranolol; resolved | resolved | confirmed | G25.71 | S — Synthetic medication side effect; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-19 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-01-19 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-01-19 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 102 | fL | 80-100 fL | High | S |
| 2026-01-19 | Platelets [#/volume] in Blood by Automated count | 172 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-01-19 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-01-19 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-01-19 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-01-19 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 108 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-01-19 | Fasting glucose [Mass/volume] in Serum or Plasma | 91 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-01-19 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.3 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-01-19 | Cholesterol [Mass/volume] in Serum or Plasma | 184 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-01-19 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 106 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-01-19 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-01-19 | Triglyceride [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-01-19 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 58 | U/L | 10-40 U/L | High | S |
| 2026-01-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 44 | U/L | 7-56 U/L | Normal | S |
| 2026-01-19 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 96 | U/L | 8-61 U/L | High | S |
| 2026-01-19 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-01-19 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 388 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-01-19 | Phosphatidylethanol [Mass/volume] in Blood | 284 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 2026-01-19 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 13 | {score} | S | ||
| 2026-01-19 | Total score [AUDIT-C] | 9 | {score} | S | ||
| 2026-02-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 11 | {score} | S | ||
| 2026-03-02 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 10-40 U/L | High | S |
| 2026-03-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 37 | U/L | 7-56 U/L | Normal | S |
| 2026-03-02 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 68 | U/L | 8-61 U/L | High | S |
| 2026-03-02 | Phosphatidylethanol [Mass/volume] in Blood | 122 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 2026-03-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-04-20 | Fasting glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-20 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-04-20 | Cholesterol [Mass/volume] in Serum or Plasma | 191 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-04-20 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 112 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-04-20 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 50 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-04-20 | Triglyceride [Mass/volume] in Serum or Plasma | 142 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-04-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 | U/L | 10-40 U/L | Normal | S |
| 2026-04-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-56 U/L | Normal | S |
| 2026-04-20 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 49 | U/L | 8-61 U/L | Normal | S |
| 2026-04-20 | Phosphatidylethanol [Mass/volume] in Blood | 46 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 2026-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-07-20 | Leukocytes [#/volume] in Blood by Automated count | 6.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-20 | Hemoglobin [Mass/volume] in Blood | 14.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-07-20 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 95 | fL | 80-100 fL | Normal | S |
| 2026-07-20 | Platelets [#/volume] in Blood by Automated count | 214 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 10-40 U/L | Normal | S |
| 2026-07-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-56 U/L | Normal | S |
| 2026-07-20 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 36 | U/L | 8-61 U/L | Normal | S |
| 2026-07-20 | Phosphatidylethanol [Mass/volume] in Blood | 16 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | Normal | S |
| 2026-07-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-06-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-06-15 | Total score [AUDIT-C] | 3 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-19 | Body height | 170 | cm | S |
| 2026-01-19 | Body weight | 64 | kg | S |
| 2026-01-19 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 2026-01-19 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-01-19 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-01-19 | Heart rate | 88 | /min | S |
| 2026-01-19 | Respiratory rate | 16 | /min | S |
| 2026-01-19 | Body temperature | 36.7 | Cel | S |
| 2026-01-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-02-02 | Body height | 170 | cm | S |
| 2026-02-02 | Body weight | 64.5 | kg | S |
| 2026-02-02 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-02-02 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-02-02 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-02-02 | Heart rate | 82 | /min | S |
| 2026-02-02 | Respiratory rate | 14 | /min | S |
| 2026-02-02 | Body temperature | 36.6 | Cel | S |
| 2026-02-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-03-02 | Body height | 170 | cm | S |
| 2026-03-02 | Body weight | 64.9 | kg | S |
| 2026-03-02 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 2026-03-02 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-03-02 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-03-02 | Heart rate | 76 | /min | S |
| 2026-03-02 | Respiratory rate | 14 | /min | S |
| 2026-03-02 | Body temperature | 36.6 | Cel | S |
| 2026-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-04-20 | Body height | 170 | cm | S |
| 2026-04-20 | Body weight | 65.7 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 74 | /min | S |
| 2026-04-20 | Respiratory rate | 14 | /min | S |
| 2026-04-20 | Body temperature | 36.7 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-07-20 | Body height | 170 | cm | S |
| 2026-07-20 | Body weight | 65.4 | kg | S |
| 2026-07-20 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 2026-07-20 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-07-20 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-07-20 | Heart rate | 70 | /min | S |
| 2026-07-20 | Respiratory rate | 14 | /min | S |
| 2026-07-20 | Body temperature | 36.6 | Cel | S |
| 2026-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-02-16 | Body height | 170 | cm | S |
| 2026-02-16 | Body weight | 64.4 | kg | S |
| 2026-02-16 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-02-16 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-02-16 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-02-16 | Heart rate | 96 | /min | S |
| 2026-02-16 | Respiratory rate | 16 | /min | S |
| 2026-02-16 | Body temperature | 36.7 | Cel | S |
| 2026-02-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-15 | Body height | 170 | cm | S |
| 2026-06-15 | Body weight | 65.8 | kg | S |
| 2026-06-15 | Body mass index (BMI) [Ratio] | 22.8 | kg/m2 | S |
| 2026-06-15 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-06-15 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-06-15 | Heart rate | 70 | /min | S |
| 2026-06-15 | Respiratory rate | 14 | /min | S |
| 2026-06-15 | Body temperature | 36.6 | Cel | S |
| 2026-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-01-19 | Establishing primary care twelve days after discharge from a first psychiatric admission: provisional diagnosis, antipsychotic monitoring baseline, first-episode workup, alcohol, sleep, and safety planning | finished | S |
| 2026-02-02 | Two-week review and psychiatry consultation with the coordinated specialty care team | finished | S |
| 2026-03-02 | Six-week review: symptoms, side effects, alcohol, sleep, and test results | finished | S |
| 2026-04-20 | Three-month review with the 12-week metabolic check | finished | S |
| 2026-07-20 | Six-month review: diagnosis, relapse prevention, movement check, and alcohol | finished | S |
| 2026-02-16 | Same-day sick visit for restlessness after an antipsychotic dose increase | finished | S |
| 2026-06-15 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Continue the antipsychotic started in hospital at the lowest effective dose, with side-effect checks at each visit (akathisia, stiffness, sedation) and monitoring to the APA and ADA/APA standard: weight at every visit, blood pressure, fasting glucose, A1c and lipids at baseline, 12 weeks and yearly, and the AIMS at baseline and every six months | completed | GL-APA-SCZ-2020, GL-ADA-APA-2004, GL-CMID-2026 | S |
| Psychiatry consultation with the first-episode psychosis coordinated specialty care team to review the provisional diagnosis and differential, the dose, the alcohol plan, and the workup for epilepsy | completed | GL-APA-SCZ-2020, GL-NIMH-CSC | S |
| First-episode workup: blood count, metabolic panel, liver tests, thyroid test, vitamin B12, HIV and syphilis tests, urine drug test, brain MRI, and a sleep-deprived EEG because of the confusion and the question of seizures | completed | GL-APA-SCZ-2020 | S |
| Alcohol care: AUDIT-C, PEth at each check to follow drinking, brief counseling with goals he chooses, thiamine, and a medicine for alcohol use disorder once the liver tests are reviewed | completed | GL-SUD-2021, GL-USPSTF-ALC-2018, GL-APA-SCZ-2020 | S |
| Coordinated specialty care: a care coordinator, individual resilience-focused therapy, education about psychosis for him and for the people he chooses, support to return to painting and selling his work, and a peer specialist | completed | GL-NIMH-CSC, GL-APA-SCZ-2020 | S |
| Sleep as treatment and as an early warning sign: regular sleep and wake times, no alcohol to get to sleep, less coffee after noon, and a plan to call the team after two nights of short sleep | completed | GL-CANMAT-BD-2018, GL-APA-SCZ-2020 | S |
| Structured safety assessment, a written safety plan with early warning signs, lethal-means counseling, the 988 Suicide & Crisis Lifeline, PHQ-9 at each visit, and safety review at every visit | completed | GL-SUICIDE-2024, GL-CMID-2026, GL-USPSTF-DEP-2023 | S |
| Akathisia: aripiprazole back to 10 mg daily, propranolol 10 mg twice daily for a few weeks, and a check of restlessness and of safety at each visit until it settles | completed | GL-APA-SCZ-2020 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| No return of psychotic symptoms and no readmission through six months, on the lowest effective antipsychotic dose | 2026-07-20 | completed | No psychotic symptoms since the six-week visit and no admission; aripiprazole 10 mg daily | S |
| PHQ-9 score below 5 by six months | 2026-07-20 | completed | PHQ-9 3 | S |
| Reduce drinking to PEth below 20 ng/mL by six months | 2026-07-20 | completed | PEth 16 ng/mL from 284 | S |
| Weight gain under 5% and normal glucose, A1c and lipids at the 12-week check | 2026-04-20 | completed | Weight 65.7 kg from 64.0 (2.7%); fasting glucose 94 mg/dL, A1c 5.4%, lipids normal | S |
| Sleep about seven hours on most nights with regular times by three months | 2026-04-20 | completed | Seven hours on most nights, in bed by midnight | S |
Structured synthetic safety assessment on 2026-01-19: current ideation present, intent absent, plan absent. Outpatient care with close follow-up. He has passive thoughts that it would be easier not to wake up, without intent, plan or preparation; the self-injury during the episode happened in confusion and without suicidal intent. His risk is higher in the months after a first episode of psychosis, while he is depressed, and while he is drinking. A written safety plan was made with him, with his own early warning signs (nights with little sleep, hearing voices, drinking more, pulling away from his friend) and what to do about each. Lethal-means counseling: he has no firearm and no access to one and agreed not to acquire one; medicines are dispensed two weeks at a time; he will keep alcohol out of the house while he is low. The 988 Suicide & Crisis Lifeline was given and saved in his phone, with the clinic number. Safety reviewed at every visit [S]